Anti-PD-1 / PD-L1-induced psoriasis from an oncological perspective

Abstract

We read with interest the letter to the editor by Bonigen et al¹ regarding the development of psoriasis during anti-programed cell death protein 1 (PD-1) therapy. The authors describe a series of 17 patients diagnosed with melanoma or lung cancer treated with anti-PD-1 drugs in first line or later. In the final analysis, they also include 4 patients previously described in the literature.

This article is protected by copyright. All rights reserved.

http://ift.tt/2m9jf9B